Pesg report: inspira technologies breaks new ground with positive clinical data for ai-powered blood sensor exceeding expectations

New york--(business wire)---- $iinn #biotech--pesg research releases an update following groundbreaking clinical evaluation results: inspira technologies* (nasdaq: iinn) has reported exceptional clinical study outcomes for its hyla blood sensor, with 96% accuracy achieved in a key parameter compared to traditional blood analyzers. this milestone achievement validates the company's ai-powered continuous blood monitoring technology and accelerates its path toward commercial deployment in multiple healthcare setting.
IINN Ratings Summary
IINN Quant Ranking